Harnessing the microbiome to treat skin disease
Leveraging skin microbiome to discover and develop novel products for skin conditions and diseases
Azitra Inc. is an emerging biotechnology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases. The Company’s technology platform offers multiple product opportunities in three areas: (1) consumer health products based on microbial strains and their components; (2) pharmaceuticals based on the delivery of biotherapeutic proteins to the skin via proprietary bacteria strains; and (3) discovery and development of novel bioactive compounds — e.g., antimicrobials and other therapeutics based on the metabolic products of commensal skin bacteria. Azitra’s lead programs are focused on eczema (atopic dermatitis) and ichthyosis vulgaris, inflammatory skin conditions, dry or irritated skin, and orphan skin diseases including Netherton syndrome.